- Home
- CNMD vs GHRS Comparison
CNMD vs GHRS Comparison
Compare CNMD & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNMD | GHRS |
|---|---|---|
| Founded | 1970 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 947.2M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNMD | GHRS |
|---|---|---|
| Price | $35.50 | $21.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $46.25 | $41.38 |
| AVG Volume (30 Days) | ★ 389.1K | 255.2K |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $1,374,724,000.00 | N/A |
| Revenue This Year | $0.82 | N/A |
| Revenue Next Year | $5.48 | N/A |
| P/E Ratio | $24.17 | ★ N/A |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $33.21 | $10.67 |
| 52 Week High | $60.80 | $24.66 |
Technical Indicators
Market Signals| Indicator | CNMD | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 60.61 |
| Support Level | $33.21 | $12.41 |
| Resistance Level | $38.70 | $22.88 |
| Average True Range (ATR) | 1.69 | 1.33 |
| MACD | -0.13 | -0.07 |
| Stochastic Oscillator | 6.60 | 67.71 |
Price Performance
Historical ComparisonAbout CNMD CONMED Corporation
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.